Bionime Announces Board Approval of Q1 2026 Consolidated Financial Report
📋 Article Processing Timeline
- 📰 Published: May 13, 2026 at 09:00
- 🔍 Collected: May 14, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 15, 2026 at 08:20 (24h 19m after Collected)
Bionime Corporation announced on May 13, 2026, the board's approval of its Q1 2026 consolidated financial statements. For the period Jan 1 to Mar 31, 2026, cumulative operating revenue was NT$405 million, with an operating gross profit of NT$122 million but an operating loss of NT$88 million. The net loss attributable to owners of the parent was NT$79 million, resulting in a basic loss per share of NT$1.09. Total assets at the end of the period were NT$5,654 million.